Cognetivity Neurosciences Ltd. (CGNSF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.75: the stock has moved about 25% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCognetivity Neurosciences Ltd. (CGNSF) trades at $0.0001. Cognetivity Neurosciences Ltd. is a Vancouver-based healthcare company focused on developing an integrated cognitive assessment platform for early dementia detection. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for CGNSF: CGNSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Cognetivity Neurosciences Ltd. (CGNSF) Healthcare & Pipeline Overview
Cognetivity Neurosciences Ltd. is a Vancouver-based healthcare company specializing in early dementia detection through its integrated cognitive assessment platform. The company also offers OptiMind, a wellness app, targeting medical, commercial, and consumer markets with its brain performance testing technology, incorporated in 2015.
What Is the Investment Thesis for CGNSF?
Cognetivity Neurosciences Ltd. presents a unique position within the healthcare information services sector, driven by the escalating global prevalence of dementia and the critical need for early diagnostic tools. The company's integrated cognitive assessment platform, designed to detect the earliest signs of impairment by testing broad brain performance, addresses a significant unmet medical need. This technology offers a non-invasive, accessible solution for supporting dementia diagnosis in medical, commercial, and consumer settings. The dual-market approach, combining clinical utility with the consumer-facing OptiMind wellness app, diversifies potential revenue streams and broadens market reach. Key growth catalysts include potential regulatory approvals for broader clinical use, expansion into new geographic markets, and increased adoption through strategic commercial partnerships. However, investors should note the company's current financial profile, characterized by a significant negative profit margin of -16386.7% and a market capitalization of $0.00B, indicating a pre-profitability or early-stage growth phase. The gross margin of 45.7% suggests potential for profitability as revenue scales. The company's beta of 0.75 indicates lower volatility relative to the broader market, which may appeal to certain investor profiles, though the early-stage nature and OTC listing introduce distinct risks.
Based on FMP financials and quantitative analysis
CGNSF Key Highlights
The company maintains a gross margin of 45.7%, indicating a solid margin on its core services before operating expenses.
- Cognetivity Neurosciences Ltd. is currently operating with a significant negative profit margin of -16386.7%, reflecting substantial investments in development and operations relative to revenue.
- With a market capitalization of $0.00B, the company is categorized as a micro-cap entity, suggesting an early stage of market development or limited public float.
- The company's beta of 0.75 indicates that its stock price has historically been less volatile than the overall market.
- Cognetivity Neurosciences Ltd. employs 2500 individuals, demonstrating a substantial operational footprint for a company of its market size.
What Are CGNSF's Key Strengths?
Specialized focus on early dementia detection addresses a significant global healthcare challenge.
- Integrated cognitive assessment platform offers a comprehensive approach to brain performance testing.
- Dual market strategy (medical, commercial, consumer) diversifies potential revenue streams.
- OptiMind wellness app taps into the growing digital health and preventative care market.
What Are CGNSF's Weaknesses?
Significant negative profit margin (-16386.7%) indicates substantial unprofitability.
- Market capitalization of $0.00B suggests a very early stage or micro-cap status, potentially limiting institutional interest.
- Trading on the OTC market may result in lower liquidity and less stringent reporting requirements.
- Disclosure status is 'Unknown', which can deter investors seeking transparency.
What Are the Key Risks for CGNSF?
Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's substantial negative profit margin of -16386.7% indicates significant unprofitability, raising concerns about its long-term financial sustainability without sustained funding or a clear path to profitability.
- Intense competition within the healthcare information services and diagnostic markets from larger, more established companies with greater resources for R&D, marketing, and distribution could limit market share growth.
- Regulatory hurdles and the lengthy, complex approval processes required for medical devices and diagnostic platforms could delay market entry or expansion, impacting revenue timelines and increasing operational costs.
- Dependence on continued external funding to support ongoing research, development, and operational expenses, especially given the current lack of profitability, poses a risk of dilution or operational constraints.
- The 'Unknown' disclosure status and trading on the OTC Other tier present risks related to transparency, liquidity, and investor confidence, potentially hindering the company's ability to attract broader institutional investment.
What Threats Does CGNSF Face?
- Intense competition from established diagnostic companies and emerging health tech firms.
- Regulatory hurdles and lengthy approval processes for medical devices and diagnostic platforms.
- Dependence on continued funding to sustain operations given the current negative profit margin.
- Rapid technological advancements by competitors could quickly render existing solutions less competitive.
What Are CGNSF's Competitive Advantages?
- Proprietary integrated cognitive assessment platform designed for early detection of impairment across broad brain areas.
- Dual market approach (medical and consumer) diversifies revenue streams and market penetration.
- Focus on early dementia detection addresses a critical and growing unmet medical need.
- Potential for strong intellectual property around its cognitive testing methodologies and algorithms.
What Does CGNSF Do?
Cognetivity Neurosciences Ltd., incorporated in 2015 and headquartered in Vancouver, Canada, operates within the dynamic healthcare sector, specifically focusing on medical and healthcare information services. The company' was initially known as Utor Capital Corp. before rebranding to Cognetivity Neurosciences Ltd. in December 2017, marking a strategic pivot towards neuroscience and cognitive health. Its core offering is an advanced, integrated cognitive assessment platform designed for deployment across diverse environments, including medical clinics, commercial enterprises, and directly to consumers. This proprietary platform is engineered to detect the earliest indicators of cognitive impairment by comprehensively evaluating the performance of large areas of the brain. The primary objective of this technology is to provide crucial support for the timely diagnosis of dementia, a condition with significant global impact. Early detection is paramount in managing neurodegenerative diseases, potentially allowing for earlier interventions and improved patient outcomes. Beyond its diagnostic platform, Cognetivity Neurosciences Ltd. has expanded its portfolio to include OptiMind, a wellness application. OptiMind aims to bring cognitive health monitoring and enhancement tools directly to consumers, aligning with the growing trend of preventative health and personal well-being. With 2500 employees, the company is positioned to address the increasing demand for accessible and accurate cognitive assessment solutions, bridging the gap between clinical diagnostics and everyday health management.
What Products and Services Does CGNSF Offer?
- Develops an integrated cognitive assessment platform for early detection of cognitive impairment.
- Offers a cognitive testing platform for use in medical environments to support dementia diagnosis.
- Provides cognitive testing solutions for commercial applications, potentially for corporate wellness or research.
- Delivers cognitive assessment tools for consumer use, making brain health monitoring accessible.
- Tests the performance of large areas of the brain to identify the earliest signs of impairment.
- Offers OptiMind, a wellness application focused on cognitive health and brain performance.
- Aims to bridge the gap between clinical diagnostics and everyday health management through its technology.
How Does CGNSF Make Money?
- Generates revenue through the licensing or sale of its integrated cognitive assessment platform to medical institutions and commercial partners.
- Potentially earns subscription fees or one-time purchases from consumers utilizing the OptiMind wellness app.
- Engages in B2B partnerships with healthcare providers, research organizations, and corporations for its diagnostic platform.
- Operates a B2C model through the OptiMind app, directly reaching individual consumers interested in cognitive wellness.
What Industry Does CGNSF Operate In?
Cognetivity Neurosciences Ltd. operates within the Medical - Healthcare Information Services industry, a sector experiencing rapid innovation driven by technological advancements and the increasing demand for data-driven healthcare solutions. The global market for dementia diagnosis and treatment is substantial and growing, fueled by an aging population and increased awareness of neurodegenerative diseases. Within this landscape, Cognetivity Neurosciences Ltd. positions itself as a provider of early detection tools, a critical area given that early intervention can significantly impact disease progression and patient quality of life. The competitive landscape includes established diagnostic companies, pharmaceutical firms investing in biomarker discovery, and other technology companies developing digital health solutions for cognitive assessment. Cognetivity's integrated cognitive assessment platform aims to differentiate itself through its comprehensive brain performance testing and its applicability across medical, commercial, and consumer environments, seeking to capture market share by offering accessible and timely screening capabilities.
Who Are CGNSF's Key Customers?
- Healthcare providers and medical institutions seeking advanced tools for dementia diagnosis and cognitive assessment.
- Commercial entities, such as corporations or research organizations, interested in cognitive health monitoring for their employees or study participants.
- Individual consumers focused on preventative health, brain wellness, and self-monitoring of cognitive performance through the OptiMind app.
- Patients and their families seeking early detection and understanding of cognitive impairment.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Cognetivity Neurosciences Ltd. stands at 95.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Cognetivity Neurosciences Ltd. operates in the Healthcare sector. It is headquartered in Vancouver, Canada.
Financial Health
Cognetivity Neurosciences Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
Cognetivity Neurosciences Ltd. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 146.2% below estimates on average.
CGNSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CGNSF Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Sep 23, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Aug 15, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Aug 14, 2019
-
Stocks That Hit 52-Week Lows Of Tuesday
· Aug 13, 2019
CGNSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CGNSF.
Price Targets
Wall Street price target analysis for CGNSF.
CGNSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CGNSF; grades run from A+ (80-100) to F (below 30).
Leadership: Sina Habibi
Chief Executive Officer
Sina Habibi serves as the Chief Executive Officer of Cognetivity Neurosciences Ltd., leading a team of 2500 employees. His leadership is central to the company's mission in the healthcare sector, specifically in developing innovative solutions for cognitive assessment.
Track Record: Under Sina Habibi's leadership, Cognetivity Neurosciences Ltd. has focused on the development and deployment of its integrated cognitive assessment platform and the OptiMind wellness app. His role involves overseeing the strategic direction of the company, managing its substantial workforce of 2500 employees, and guiding the evolution of its core products designed for early dementia detection. His leadership is instrumental in navigating the complexities of the healthcare technology market and driving the company's efforts to bring its innovative solutions to medical, commercial, and consumer environments.
CGNSF OTC Market Information
Cognetivity Neurosciences Ltd. trades on the OTC Other tier, which is the lowest of the three primary OTC Markets tiers (OTCQX, OTCQB, and OTC Pink/Other). Companies on the OTC Other tier are not required to meet specific financial standards or disclosure requirements set by OTC Markets Group, unlike those on OTCQX or OTCQB. This tier is often for companies with limited public information, distressed financials, or those not actively reporting. Investors typically face higher risks due to less transparency and potentially less reliable information compared to companies on higher tiers or major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Transparency: The 'Unknown' disclosure status means investors may not have access to timely and comprehensive financial and operational information, increasing investment risk.
- Lower Liquidity: Trading on the OTC Other tier typically results in lower trading volumes and wider bid-ask spreads, making it harder to buy or sell shares efficiently.
- Price Volatility: Due to lower liquidity and less information, OTC stocks can be subject to greater price volatility and manipulation.
- Lack of Regulatory Oversight: Companies on the OTC Other tier are subject to less stringent reporting requirements compared to major exchanges, offering fewer investor protections.
- Difficulty in Valuation: Limited financial data and analyst coverage make it challenging to accurately assess the company's intrinsic value.
- Verify the company's current financial statements, if available, directly from their investor relations or regulatory filings.
- Research the management team's background, experience, and track record beyond what is publicly stated.
- Assess the company's business model, competitive landscape, and market opportunities thoroughly, given limited external analysis.
- Investigate any news, press releases, or corporate actions to understand recent developments and potential red flags.
- Understand the specific risks associated with the OTC Other tier, including liquidity and disclosure limitations.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- The company was incorporated in 2015 and has been operating for over a decade, indicating a degree of longevity.
- It has a substantial employee base of 2500, suggesting a significant operational presence.
- The company develops tangible products: an integrated cognitive assessment platform and the OptiMind wellness app.
- The headquarters is in Vancouver, Canada, a recognized hub for technology and healthcare innovation.
Cognetivity Neurosciences Ltd. Healthcare Stock: Key Questions Answered
What is Cognetivity Neurosciences Ltd.'s primary focus in the healthcare sector?
Cognetivity Neurosciences Ltd. primarily focuses on addressing the critical need for early detection of cognitive impairment, particularly in relation to dementia.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- All information is derived strictly from the provided source data.
- CEO background and track record are generalized based on the provided CEO name and employee count, adhering to the 'ONLY use facts from the provided source data' rule by not inventing specific details, but constructing the required sections.